Company intelligence
MABPLEX USA, INC
MabPlex, your trusted CDMO partner for mAbs and ADC
About MABPLEX USA, INC
MABPLEX USA, INC offers our partners contract services from DNA to finished drug product.
Verified activity
Signals from MABPLEX USA, INC
12 published signals
Products & Services
MABPLEX USA, INC scientists specialize in adapting conjugation chemistries for non-traditional payloads.
Reported by MABPLEX USA, INC
Products & Services
MABPLEX USA, INC provides specialized solubility protocols for non-cytotoxic payloads.
Reported by MABPLEX USA, INC
Products & Services
MABPLEX USA, INC provides comprehensive stability profiles for novel conjugates.
Reported by MABPLEX USA, INC
Products & Services
MABPLEX USA, INC provides a comprehensive analytical suite to validate the pharmacological properties of conjugates.
Reported by MABPLEX USA, INC
Research & Knowledge
MABPLEX USA, INC offers extensive experience in Topo1i conjugation and provides analytical validation for linker stability and drug-antibody ratio consistency.
Reported by MABPLEX USA, INC
Products & Services
MABPLEX USA, INC provides integrated oversight to synchronize complex conjugation cycles for dual-payload ADCs.
Reported by MABPLEX USA, INC
Products & Services
MABPLEX USA, INC offers a one-stop-shop solution for bispecific ADCs, handling everything from cell line development to final drug product.
Reported by MABPLEX USA, INC
Research & Knowledge
MABPLEX USA, INC reports that recent data shows a consolidation toward well-validated targets like HER-2 and TROP-2, which appeared in 60% of recent abstracts at AACR 2026.
Reported by MABPLEX USA, INC
Products & Services
MABPLEX USA, INC provides the regulatory track record necessary to validate next-generation HER-2 ADCs and TROP-2 targets.
Reported by MABPLEX USA, INC
Research & Knowledge
MABPLEX USA, INC reported that the AACR 2026 report identified 300 distinct drug conjugates, marking nearly a 20% growth from the previous year.
Reported by MABPLEX USA, INC
Research & Knowledge
MABPLEX USA, INC reported that the AACR 2026 report identified 300 distinct drug conjugates, marking nearly a 20% growth from the previous year.
Reported by Mun Ching Lee
Partnerships
MABPLEX USA, INC announced the new collaboration agreement between Roche and C4 Therapeutics to advance degrader antibody conjugates.
Reported by MABPLEX USA, INC